IOL, CataractNCT07099079
Post-Market Clinical Follow-Up Study on the Rotational Stability of an Intraocular Lens After Cataract Surgery
An observational study of IOL, Cataract, run by Rayner Intraocular Lenses Limited.
Trial summary
The goal of this post-market, prospective study at multiple clinics is to evaluate the rotational stability of the RayOne Model RAO800S non-toric monofocal intraocular lens with orientation marks in adult patients undergoing cataract surgery in both eyes. Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- IOL, Cataract
- How many people
- 92 participants
- Where
- No sites listed yet
- Study dates
- Nov 2026to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- Adult, Older adult
Study population: Patients aged 22 years or older who are scheduled for bilateral cataract surgery as part of routine clinical care and are in accordance with the study's inclusion and exclusion criteria.
Eligible subjects must meet all the following inclusion criteria in both eyes.
- Male or female, 22 years or older at the pre-operative visit who have cataract in both eyes and who are eligible for phacoemulsification cataract surgery
- Subjects who are projected to have best corrected distance visual acuity 0.20 logMAR (20/30) or better in both eyes after IOL implantation by investigator estimation
- Clear intraocular media other than cataract
- Contact lens wearers must demonstrate stability of biometry in both eyes
- Have the capability to understand and sign an EC approved informed consent form and privacy authorization in accordance with local regulations
- Female subjects must be 1-year postmenopausal, surgically sterilized, or if childbearing potential must use a stabilized and acceptable form of contraception from the beginning throughout the end of the study. Stabilized and acceptable contraception methods include at least one of the following: intrauterine (intrauterine device) or hormonal (oral, injection, patch, implant, ring) for at least 3 months, barrier with spermicide (condom, diaphragm), or abstinence.
- Have pre-existing corneal astigmatism not exceeding 1.25 D in both eyes as determined by keratometry
- Dilated pupil size 5.5 mm or greater to allow visualization of the IOL orientation marks post-operatively in both eyes
Eligible subjects must not meet any of the following exclusion criteria. Subjects may not participate if either eye meets any of the ocular exclusion criteria:
- Previous intraocular, corneal, or retinal detachment surgery, including corneal transplant, LASIK / LASEK / PRK, SMILE, astigmatic keratotomy and limbal relaxing incisions in any eye
- Diagnosed degenerative visual disorders (e.g. macular degeneration, retinal detachment, proliferative diabetic retinopathy, or other retinal disorders) that are predicted to cause future acuity losses to a level of 0.20 logMAR (20/30) or worse
- Significant anterior segment pathology that might increase intraoperative risk or compromise IOL stability (e.g. pseudoexfoliation syndrome, any iris pathology)
- Subjects with conditions associated with increased risk of zonular rupture (that may affect post-operative centration or tilt of IOL) in any eye
- Potentially occludable angle or ciliary body tumor, or other pathology that might increase risk to subject safety, based on adequate diagnostics e.g. gonioscopic, anterior OCT observation
- Subjects reasonably expected to require secondary ocular surgical intervention or laser treatment (other than YAG capsulotomy)
- Subjects with clinically significant corneal pathology, potentially affecting corneal topography
- Subjects with traumatic cataract in any eye
- Currently participating in a drug or device clinical trial, or having participated in such a trial within 30 days prior to the pre-operative visit
- Subjects with any other serious ocular pathology (e.g. severe dry eye, history of intraocular inflammation, history of retinal surgery or retinal laser procedure) or underlying systemic medical condition (e.g., uncontrolled diabetes) or circumstance that, based on the investigator's judgment, poses a concern for the subjects' safety or could confound the results of the study
- Clinically significant, uncontrolled glaucoma with expected negative impact on IOL Rotational Stability and / or visual acuity outcomes in one or both eyes
- Use of medications known to interfere with visual performance, pupil dilation, or iris structure within 30 days of the pre-operative visit, at the discretion of the investigator
- Pregnant or nursing females
- Pre-operative corneal astigmatism above 1.25D as determined by keratometry
- Irregular astigmatism in any eye Additional Exclusion Criteria at the Time of Surgery: Subjects who do not meet exclusion criteria described in section 6.2 and are enrolled in the study may present findings during surgery that preclude inclusion of performance data in the investigation and thus need to be excluded from data collection post operatively. The following general exclusion criteria shall be considered during surgery for either eye:
- zonular instability;
- need for iris manipulation;
- capsular fibrosis or other opacity;
- inability to fixate IOL in desired position
If the IOL has touched the eye, it should be noted if the reason for exclusion is related to the IOL itself and/or any (e.g. IOL or insertion device defect causing capsular damage, malfunction of insertion device).
If the IOL has touched the eye, the subject should be followed, for safety, until completion of the investigation.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Post-Market Clinical Follow-up Trial to Investigate the Rotational Stability of the Hydrophobic Intraocular Lens RAO800S
The goal of this post-market, prospective study at multiple clinics is to evaluate the rotational stability of the RayOne Model RAO800S non-toric monofocal intraocular lens with orientation marks in adult patients undergoing cataract surgery in both eyes. The main question it aims to answer is how stable the RayOne RAO800S lens is approximately 5 months (120 to 150 days) after surgery day. Participants are adults already scheduled to undergo cataract surgery as part of clinical routine. They will be asked to attend regular follow-up visits at the clinic, where eye images will be taken to assess the rotational stability of the implanted lens.
Read the detailed description
This post-market clinical follow-up (PMCF) study is a prospective, multicenter investigation in European sites. It evaluates the rotational stability of the RayOne Model RAO800S, a non-toric monofocal intraocular lens with orientation marks, following bilateral implantation. Participants will be assessed approximately 5 months (120 to 150 days) post-operatively.
- Conditions
- IOL, Cataract
- Medical subject headings
- Intraocular Lymphoma, Cataract
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Cataract patients | Adult patients scheduled for routine bilateral cataract surgery as part of their standard clinical care. All participants receive the RayOne RAO800S non-toric monofocal intraocular lens with orientation marks. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Effectiveness Endpoint - IOL rotation
Percentage of RayOne Model RAO800S IOLs with IOL rotation at Visit 4 (as determined by photographic method using baseline image at day of surgery) less than
- 10 degrees in 90% of the cases as described in ISO 11979-7:2024.
- 20 degrees in 95% of the cases as described in ISO 11979-7:2024.
Measured: 120 to 150 days post-operatively (Visit 4)
Secondary outcomes (3)
Secondary Effectiveness Endpoints - Stability of IOL axis orientation
Stability of IOL axis orientation, expressed as percentage of IOLs that rotate ≤ 5 degrees postoperatively between 30 to 60 days (Visit 3) and 120 to 150 days (Visit 4) as described in the ANSI Z80.30-2018. This criterium is passed if 90% of the IOLs in the treated eyes rotate ≤ 5 degrees between the mentioned visits.
Measured: 120 to 150 days post-operatively (Visit 4)
Secondary Effectiveness Endpoints - Axis misalignment
Axis misalignment, defined as the absolute difference between intended IOL axis orientation and Visit 4, (as determined by photographic method using baseline image at the day of surgery) shall be less than
- 10 degrees in 90% of the cases as described in ANSI Z80.30-2018
- 20 degrees in 95% of the cases as described in ANSI Z80.30-2018.
Measured: 120 to 150 days post-operatively (Visit 4)
Secondary Safety Endpoints - Rate of CDVA 0.30 logMAR
Rate of CDVA 0.30 logMAR or better at 120 to 150 days post-operatively (Visit 4) shall not exceed the ISO SPE threshold rates as described in ISO 11979-7:2024 (Table E.3)
Measured: 120 to 150 days post-operatively (Visit 4)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2025
- Study startNov 2026 (estimated)
- Primary completionNov 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for IOL, CataractStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 92 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rayner Intraocular Lenses Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07099079
- Sponsor's protocol ID
- HRSS-2025-01
- Status last verified
- Sep 2026
- First submitted
- 15 Jul 2025
- Last updated
- 10 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Post-Market Clinical Follow-up Trial to Investigate the Rotational Stability of the Hydrophobic Intraocular Lens RAO800S
- ClinicalTrials.gov ID
- NCT07099079
- Acronym / sponsor ID
- HRSS-2025-01
- Conditions
- IOL, Cataract
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 92 participants (estimated)
- Lead sponsor
- Rayner Intraocular Lenses LimitedIndustry (pharma, biotech, devices)
- Study start
- Nov 2026 (estimated)
- Primary completion
- Nov 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 1 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this post-market, prospective study at multiple clinics is to evaluate the rotational stability of the RayOne Model RAO800S non-toric monofocal intraocular lens with orientation marks in adult patients undergoing cataract surgery in both eyes. The main question it aims to answer is how stable the RayOne RAO800S lens is approximately 5 months (120 to 150 days) after surgery day. Participants are adults already scheduled to undergo cataract surgery as part of clinical routine. They will be asked to attend regular follow-up visits at the clinic, where eye images will be taken to assess the rotational stability of the implanted lens.
Detailed description
This post-market clinical follow-up (PMCF) study is a prospective, multicenter investigation in European sites. It evaluates the rotational stability of the RayOne Model RAO800S, a non-toric monofocal intraocular lens with orientation marks, following bilateral implantation. Participants will be assessed approximately 5 months (120 to 150 days) post-operatively.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cataract patients | – | –Adult patients scheduled for routine bilateral cataract surgery as part of their standard clinical care. All participants receive the RayOne RAO800S non-toric monofocal intraocular lens with orientation marks. |
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients aged 22 years or older who are scheduled for bilateral cataract surgery as part of routine clinical care and are in accordance with the study's inclusion and exclusion criteria.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Primary Effectiveness Endpoint - IOL rotation
Time frame: 120 to 150 days post-operatively (Visit 4)
Percentage of RayOne Model RAO800S IOLs with IOL rotation at Visit 4 (as determined by photographic method using baseline image at day of surgery) less than * 10 degrees in 90% of the cases as described in ISO 11979-7:2024. * 20 degrees in 95% of the cases as described in ISO 11979-7:2024.
3 secondary outcomes
Secondary Effectiveness Endpoints - Stability of IOL axis orientation
Time frame: 120 to 150 days post-operatively (Visit 4)
Secondary Effectiveness Endpoints - Axis misalignment
Time frame: 120 to 150 days post-operatively (Visit 4)
Secondary Safety Endpoints - Rate of CDVA 0.30 logMAR
Time frame: 120 to 150 days post-operatively (Visit 4)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2026.
Related trials for IOL, Cataract
Not yet recruiting
Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction
Aphakia, Postcataract
Not yet recruitingObservational study
PureSee/Odyssey Mix-and-Match IOL
Cataract
Recruiting
Clinical Evaluation of a Novel Trifocal IOL
Aphakia, Cataract
Not yet recruitingObservational study
Postoperative Outcome Verification of Discrepant Toric IOL Calculator Recommendations After Cataract Surgery
Cataract
Not yet recruitingPhase 4
Clinical Evaluation of Visual Performance, Spectacle Independence, and Patient Satisfaction With TECNIS PureSee Mini-Monovision and TECNIS PureSee-TECNIS Odyssey Mix-Match
Presbyopia Correction, Presbyopia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of IOL, Cataract, run by Rayner Intraocular Lenses Limited.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pavel Stodulka, MD, PhD, FEBOS-CR (+420 577 202 2, stodulka@lasik.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Effectiveness Endpoint - IOL rotation (time frame: 120 to 150 days post-operatively (Visit 4)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.